Growth Velocity Reduced with Once-Daily Fluticasone Furoate Nasal Spray in Prepubescent Children with Perennial Allergic Rhinitis

Lee, Laurie A.; Sterling, Richard K.; Máspero, Jorge; Clements, Diane; Ellsworth, Anna; Pedersen, Søren

doi:10.1016/j.jaip.2014.04.008

Cited by 32 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 55 Fluticasone furoate, similarly, has low bioavailability, but the use of a double-dose 110 mcg per day has been associated with reduction in growth. 56 It is sensible to use the lowest dose of minimally bioavailable INS needed to maintain control and to administer this in the morning. ‘Holidays’ from treatment are ineffective in reduction of systemic effects and are liable to result in loss of control.…”

Section: Investigationsmentioning

confidence: 99%

Optimal management of allergic rhinitis

Scadding

2015

Arch Dis Child

View full text Add to dashboard Cite

Allergic rhinitis (AR), the most common chronic disease in childhood is often ignored, misdiagnosed and/or mistreated. Undertreated AR impairs quality of life, exacerbates asthma and is a major factor in asthma development. It can involve the nose itself, as well as the organs connected with the nose manifesting a variety of symptoms. Evidence-based guidelines for AR therapy improve disease control. Recently, paediatric AR guidelines have been published by the European Academy of Allergy and Clinical Immunology and are available online, as are a patient care pathway for children with AR and asthma from the Royal College of Paediatrics and Child Health. Management involves diagnosis, followed by avoidance of relevant allergens, with additional pharmacotherapy needed for most sufferers. This ranges, according to severity, from saline sprays, through non-sedating antihistamines, oral or topical, with minimally bioavailable intranasal corticosteroids for moderate/severe disease, possibly plus additional antihistamine or antileukotriene. The concept of rhinitis control is emerging, but there is no universally accepted definition. Where pharmacotherapy fails, allergen-specific immunotherapy, which is uniquely able to alter long-term disease outcomes, should be considered. The subcutaneous form (subcutaneous immunotherapy) in children has been underused because of concerns regarding safety and acceptability of injections. Sublingual immunotherapy is both efficacious and safe for grass pollen allergy. Further studies on other allergens in children are needed. Patient, carer and practitioner education into AR and its treatment are a vital part of management.

show abstract

Section: Investigationsmentioning

confidence: 99%

Optimal management of allergic rhinitis

Scadding

2015

Arch Dis Child

View full text Add to dashboard Cite

show abstract

“…The adverse effects most commonly experienced with the use of intranasal corticosteroids are headache, throat irritation, epistaxis, stinging, burning, and nasal dryness. Although the use of intranasal corticosteroids has raised concern for potential systemic adverse effects, including the suppression of the hypothalamic-pituitary axis [12], the products currently available have not been shown to have such effects.…”

Section: Discussionmentioning

confidence: 99%

Is the Effect and Safety of Single Daily Dose of Fluticasone Nasal Spray Better than Alternate Day Regimen in Allergic Rhinitis?

Gupta¹,

Ts²,

Garg³

et al. 2017

Clin Exp Pharmacol

View full text Add to dashboard Cite

show abstract

“…34,35 A recent study evaluated the effect of the newer fluticasone furoate nasal spray (FFNS) on growth in young children. 36 Due to the large sample size and narrow age range of the patients studied, investigators were able to determine a small, but statistically significant reduction in growth velocity after 52 weeks of treatment with FFNS once daily compared with placebo. 36 No clinically significant adverse events were observed on any other safety profile end points.…”

Section: Efficacymentioning

confidence: 99%

Management of Allergic Rhinitis: A Review for the Community Pharmacist

May

Dolen

2017

Clinical Therapeutics

108

View full text Add to dashboard Cite

Many of these medications are available over the counter in the pharmacy, and the community pharmacist plays an important role as part of the patient's health care team in managing this disease. Pharmacotherapy is patient-specific, based on type, duration, and severity of symptoms, comorbidities, prior treatment, and patient preference. This article aims to provide an overview of the pathophysiology, available treatment options, guideline recommendations, and role of the pharmacist for this disease.

show abstract

Growth Velocity Reduced with Once-Daily Fluticasone Furoate Nasal Spray in Prepubescent Children with Perennial Allergic Rhinitis

Cited by 32 publications

References 15 publications

Optimal management of allergic rhinitis

Optimal management of allergic rhinitis

Is the Effect and Safety of Single Daily Dose of Fluticasone Nasal Spray Better than Alternate Day Regimen in Allergic Rhinitis?

Management of Allergic Rhinitis: A Review for the Community Pharmacist

Contact Info

Product

Resources

About